TABLE 6.

Comparison of pharmacokinetic date between current and reported studies

Parametera	Mean value (±SD) by method and patient age and gender
	Population PK			Noncompartmental method (Barbhaiya et al. [36])
	Current study		Lima-Rogel et al. (35)	Young adult (n = 24)f		Elderly adult (n = 24)g
	≥30 days (n = 47)	<30 days (n = 44)	6–58 days (n = 31)	Male	Female	Male	Female
CL (ml/min/kg)	2.59 ± 1.10	1.08 ± 0.38	1.20 ± 0.49	1.54 ± 0.22	1.56 ± 0.22	1.11 ± 0.12	1.22 ± 0.19
V or Vss (liters/kg)	0.37 ± 0.07	0.39 ± 0.09	0.41 ± 0.12	0.21 ± 0.02	0.21 ± 0.02	0.23 ± 0.03	0.24 ± 0.06
t1/2 (h)	2.45 ± 1.77c	4.68 ± 1.69c	4.32 ± 1.8	2.26 ± 0.51	2.15 ± 0.33	3.05 ± 0.50	2.92 ± 0.38
Css min (μg/ml)b	6.38 ± 13.40	26.43 ± 18.24	18.39 ± 13.3e	NAd
Css max (μg/ml)b	171.89 ± 23.47	190.81 ± 28.36	120.9 ± 38.5e

^aCL, clearance; V, volume of distribution; Vss; steady-state volume of distribution; Css min, minimum concentration at steady state; Css max, maximum concentration at steady state; t_1/2, half-life.

^bActual milligram doses that patients received were used for estimation. Dosing intervals were set as q12h for estimation. Actual milligram doses that patients received were 48.2 ± 5.9 mg/kg/dose (pediatric; age ≥30 days) and 49.4 ± 2.8 mg/kg/dose (neonates; age <30 days).

^cElimination half-life value.

^dNA, not applicable.

^eDose of 50 mg/kg q12h.

^fMean age, 31.5 years.

^gMean age, 68 years.